Alzheon
PrivateLast Round
Series E
Jun 12, 2024
Est. Valuation
$404.13M
Total Funding Raised
$260.9M
Company Overview
Alzheon is a biopharmaceutical company that develops a small molecule-based drug discovery platform aimed at treating Alzheimer's disease and other neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B2C
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alzheon Comparables
Compare Alzheon with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AriBio | 78% | |
| Annovis Bio, Inc. | 76% | |
| Acumen Pharmaceuticals | 74% | |
Alzheon Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Jun 12, 2024 | ||||
| Series D | Apr 14, 2022 | ||||
| Grant | Aug 20, 2020 | ||||
| Series C | Apr 24, 2019 | ||||
| IPO | Jan 16, 2019 | ||||
Series B | Aug 31, 2018 |
Key People
Founding team and executive leadership
Alzheon Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ally Bridge Group | Convertible Debt, Series A, Series B |
| The Benchmark Company | IPO |
| H.C. Wainwright & Co. | IPO |
| National Institute on Aging | Grant |
| National Institute on Aging | Grant |
| ThinkEquity | IPO |
| Citigroup | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 21, 2026
Presented new biomarker data for oral anti-amyloid therapy at AD/PD 2026.
- Mar 21, 2026
Presented new data at the AD/PD 2026 conference on March 21, 2026.
Alzheon Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alzheon's valuation, stock price, and market status.